Researcher's surprising finding could lead to glanders vaccine

Results from this western blot analysis suggest that B. thailandensis ATPK01 (lane 5) contains immunogens that would generate protective immunity against B. mallei infection.

(Medical Xpress)—Apichai Tuanyok dedicated several years to working on a bacterial pathogen in Canada, but his breakthrough occurred in Flagstaff with an unexpected finding on a routine lab report.

Although the Tuanyok is investigating at Northern Arizona University is closely related to, but not the same, as the one he had researched in Canada, the results felt like a payoff for all the effort.

"I emailed many people that day," Tuanyok said, recalling his excitement at the lab report filed by his graduate student. What Tuanyok wrote in the email was that he possibly had found a vaccine target for glanders, a severe infectious disease that is usually limited to horses and donkeys but has potential as a biowarfare agent.  

Follow-up tests at NAU's Center for and Genomics (MGGen), where Tuanyok is an assistant research professor of biological sciences, have convinced Tuanyok that "we have the right target, but we have to identify further what bacterial species would be a good candidate" for an effective vaccine.

What Tuanyok found was that a common known as ATPK 1 plays a role in generating against glanders infection, with a 70 percent survival rate among infected .

Glanders, caused by the bacterium Burkholderia mallei, occurs in several countries in the Middle East, Mediterranean and South America. Human infection is uncommon but when it occurs, the bacterium is highly antibiotic resistant. No vaccine currently exists.

The Department of Defense has taken an interest because the bacterium, in aerosolized form, could be used as a bioweapon. During the , it is believed that Germany used methods to spread glanders intentionally, infecting Russian horses and mules used by the military. It was also used by the Japanese in .

Tuanyok is working on a manuscript with Paul Keim, NAU Regents' professor and director of MGGen, to describe the research and hopefully generate more funding.

It was Keim, in fact, who brought Tuanyok to the MGGen lab based on his work with melioidosis, a tropical disease that claims thousands of lives each year in Tuanyok's native Thailand. The bacterium behind that disease, Burkholderia pseudomallei, was still Tuanyok's focus when he first arrived at NAU in 2006. He may yet return to it.

"The vaccine we're working on may not be used for another disease," Tuanyok said, "but I have another idea for melioidosis and I may be able to do some work in parallel."

add to favorites email to friend print save as pdf

Related Stories

Gene against bacterial attack unravelled

Oct 28, 2008

Dutch researcher Joost Wiersinga from AMC Medical Center in Amsterdam has unravelled a genetic defense mechanism against the lethal bacteria Burkholderia pseudomallei. The research is the next step towards a vaccine against ...

Recommended for you

Global impact of the Ebola outbreak

12 minutes ago

The Ebola virus has been spreading in West Africa since March, but the current outbreak over the past few weeks has reached new heights and elevated the crisis. More than 650 people have died, and in recent days it was learned ...

S.Korea detects second foot-and-mouth case

2 hours ago

South Korea on Monday reported its second case of foot-and-mouth disease in less than a week, triggering fearful memories of a devastating 2011 outbreak that forced the culling of millions of livestock.

Ebola kills Liberian doctor, 2 Americans infected

3 hours ago

(AP)—One of Liberia's most high-profile doctors has died of Ebola, officials said Sunday, and an American physician was being treated for the deadly virus, highlighting the risks facing health workers trying ...

Hepatitis C virus genotype 1 is most prevalent worldwide

3 hours ago

In one of the largest prevalence studies to date, researchers from the U.K. provide national, regional, and global genotype prevalence estimates for the hepatitis C virus (HCV). Findings published in Hepatology, a journa ...

1 in 3000 blood donors in England infected with hepatitis E

3 hours ago

The first systematic analysis of hepatitis E virus (HEV) transmission by blood components indicates that about 1 in 3000 donors in England have HEV in their plasma. The findings, published in The Lancet, suggest that around ...

User comments